http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0615758-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fdaa64756184e715af6cb25ebc318917 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-80 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate | 1993-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67ccfb890098130a5dac5e42c7efc018 |
| publicationDate | 1994-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0615758-A1 |
| titleOfInvention | Anti-tumor vaccines |
| abstract | An immunogen suitable for use as an anti-tumor vaccine for inducing an anti-tumor immune response in cancer patients is derived from modified tumor cells and is capable of inducing an anti-tumor immune response. The immunogen is prepared by exposing tumor cells simultaneously to a crosslinking agent being a 2',3'-nucleoside or nucleotide dialdehyde at a concentration and for a time sufficient to cause crosslinking of proteins in the cell's plasma membrane and to hydrostatic pressure of about 1200-1400 atm a time sufficient to cause displacement of the proteins in the cell's plasma membranes. The exposure to said crosslinking agent and to hydrostatic pressure are preferably simultaneous. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9733612-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9625664-A1 |
| priorityDate | 1988-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 67.